Normunity, Inc., a biotechnology company creating innovative precision anti-cancer immunotherapies, is thrilled to announce the appointment of Olga Granaturova, MBA, as Chief Operating Officer and Chief Business Officer. Ms. Granaturova brings a wealth of knowledge to the table, boasting more than 25 years of experience in the biopharma industry. She is well-versed in corporate strategy, business development, R&D organization, portfolio management, and commercialization strategies in biotechnology and pharmaceutical businesses of all sizes and stages of growth.
We are thrilled to welcome Olga to the Normunity Leadership Team! Her extensive experience in business creation, financing and business development will be a tremendous asset as we continue to expand and make the most of the possibilities in immuno-oncology. Olga’s passion for entrepreneurship and vast scientific knowledge make her the perfect addition to our team as we strive to create a first-rate biotech company.
I’m thrilled to join Normunity at such an exciting time, as the company is making strides towards immune normalization in the fight against cancer. I’m eager to be a part of the development process that could lead to life-changing medicines for cancer patients. It is an honor to be part of a company that is striving to be a leader in the immuno-oncology space and I’m confident that together we can achieve great things.
Olga Granaturova is a powerhouse of diverse experience, spanning the entire value chain from R&D to commercial launch, and bringing deep expertise in business functions such as fundraising, licensing, partnering and M&A transactions. She is the co-founder and Chief Operating Officer of Parthenon Therapeutics, a biotech company creating a novel class of anti-cancer therapies. Olga has also served as VP of business development at Evotec and founder and managing partner of the life sciences consulting firm, LENUS Group, giving her hands-on experience in creating biotech start-ups as a founder, angel investor, and startup mentor. Her impressive career has seen her lead teams to deliver 20 different clinical candidates, 3 drug launches, and several multi-year, multi-million dollar deals. A recipient of a BS in Pharmaceutical Sciences from SUNY at Buffalo and a TRIUM Global MBA from the NYU Stern School of Business, HEC Paris and the London School of Economics, Olga was recently named to Inc.’s Female Founders 100 List, honoring her work as an innovator and entrepreneur. On top of this, she is co-founder and president of Brighter Ventures, a nonprofit organization advancing women-led entrepreneurship, and serves on the board
About Normunity
Normunity, Inc is a pioneering biotechnology company revolutionizing the field of immuno-oncology. Our novel approach to cancer treatment, called immune normalizers, targets novel mechanisms in order to free the body’s normal immunity against cancer. Drawing from our ongoing academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine, we have developed proprietary discovery platforms to uncover the intricate interactions between human cancer and the immune system. We are currently advancing a pipeline of immune normalizers, including initial drug programs that target mechanisms that prevent T-cells from penetrating tumors, and other barriers to normal immune function in cancer.